All News
Filter News
Found 155 articles
-
Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September 2023
9/7/2023
Viridian Therapeutics, Inc. announced that multiple abstracts featuring clinical and preclinical data on the Company’s pipeline candidates for the treatment of thyroid eye disease will be presented at the following medical meetings.
-
Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/8/2023
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the second quarter ended June 30, 2023.
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - August 04, 2023
8/4/2023
Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 140,000 shares of the Company’s common stock to two new employees on August 1, 2023.
-
Early-stage data shows that Viridian’s thyroid eye disease candidate induces clinically meaningful improvements in eye protrusion after six weeks of treatment.
-
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
7/10/2023
Viridian Therapeutics, Inc. announced positive preliminary data from its ongoing Phase 1/2 clinical trial of VRDN-001, an investigational full antagonist antibody to the insulin-like growth factor 1 receptor, in patients with chronic thyroid eye disease.
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - July 06, 2023
7/6/2023
Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 101,000 shares of the Company’s common stock to two new employees on July 5, 2023.
-
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society
6/13/2023
Viridian Therapeutics, Inc. announced that multiple abstracts featuring data on the Company’s lead investigational therapy for the treatment of thyroid eye disease will be presented at the Annual Meeting of the Endocrine Society to be held June 15-18, 2023, in Chicago, Illinois.
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 05, 2023
6/5/2023
Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 315,000 shares of the Company’s common stock to three new employees on June 1, 2023.
-
Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
5/9/2023
Viridian Therapeutics, Inc., a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, announced financial results and provided a corporate update for the first quarter ended March 31, 2023.
-
Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
5/8/2023
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse® innovative wearable drug delivery system for volumes of up to 25mL.
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2023
5/4/2023
Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 96,000 shares of the Company’s common stock to two new employees on May 1, 2023.
-
Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023
5/2/2023
Viridian Therapeutics, Inc. (NASDAQ: VRDN) today announced it will host a webcast and conference call on Tuesday, May 9, 2023 at 4:30 p.m. ET to discuss its first quarter 2023 financial results and provide a corporate update.
-
UPDATE – Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
4/20/2023
Viridian Therapeutics, Inc. announced that multiple abstracts featuring updates on the Company’s investigational therapies for the treatment of thyroid eye disease —including new preclinical research on VRDN-003—will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, to be held April 23-27, 2023, in New Orleans, Louisiana.
-
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
4/20/2023
Viridian Therapeutics, Inc. (NASDAQ: VRDN) today announced that multiple abstracts featuring updates on the Company’s investigational therapies for the treatment of thyroid eye disease (TED)—including new preclinical research on VRDN-003—will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO 2023), to be held April 23-27, 2023, in New Orleans, Louisiana.
-
Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer
4/12/2023
Viridian Therapeutics, Inc. today announced the appointment of Tony Casciano to the role of Chief Commercial Officer (CCO).
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 04, 2023
4/4/2023
Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Company’s Board of Directors or the Compensation Committee thereof, as applicable, approved the grant of non-qualified stock options to purchase an aggregate of 350,000 shares of the Company’s common stock to two new employees on March 30 and April 3, 2023, respectively.
-
Sensorion Appoints Khalil Barrage as Interim Chairman of the Board
3/31/2023
Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, announces the appointment of Khalil Barrage as Interim Chair of the Board.
-
Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
3/8/2023
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022.
-
Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society
3/7/2023
Viridian Therapeutics, Inc. today announced that multiple abstracts on VRDN-001 and VRDN-002—the Company’s investigational therapies for the treatment of thyroid eye disease (TED)—will be presented at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS), to be held March 11 to 16, 2023, in Orlando, Florida.
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 03, 2023
3/3/2023
Viridian Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 337,000 shares of the Company’s common stock to three new employees on March 1, 2023.